Liposomal Doxorubicin Market is Likely to Witness Steady Growth by 2032

The liposomal doxorubicin market is expected to grow at a 5.4% CAGR between 2022 and 2032.

The lead mining software market is expected to grow from US$ 1,240 Million in 2022 to US$ 2.1 Billion by 2032.

Because of changes in the working population's sedentary lifestyles and stressful schedules, the sales of liposomal doxorubicin pharmaceuticals are increasing, which is increasing the prevalence of these diseases and favourably boosting the liposomal doxorubicin market growth.

Liposomal doxorubicin is in high demand since it is used to treat cancer, Kaposi Sarcoma, and a range of other disorders. Because of rising cancer incidence, the development of technologically complex drug delivery techniques, increased patient awareness, and rising disposable incomes, the global liposomal doxorubicin market share is predicted to grow.

Following the failure of previous systemic treatment for ovarian cancer and AIDS-related Kaposi's sarcoma, liposomal doxorubicin sales are predicted to skyrocket. Another reason increasing demand for liposomal doxorubicin is an increase in hepatocellular cancer diagnoses and survival rates.

Furthermore, the import of the medicine was approved in the United States, which is the largest market for liposomal doxorubicin formulation, under "exercise enforcement discretion." The increased demand for liposomal doxorubicin has resulted in a growth in the importation of doxorubicin HCl liposome injections, which is expected to move the liposomal doxorubicin market ahead.

Key Players

  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd
  • Cipla Inc
  • Cadila Pharmaceuticals

Browse More Details@ https://www.futuremarketinsights.com/reports/liposomal-doxorubicin-market

Key Segments

By Products:

  • J7J (Doxil/Caelyx)
  • Sun Pharma (Lipodox)
  • Teva (Myocet)

By Application:

  • Leukemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Kaposi Sarcoma

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more